Covid-19 Intranasal vaccine may protect from infection entering into the body
Bharat Biotech has started phase-3 clinical trials of its intranasal Covid-19 vaccine as a booster dose, as soon as it has got regulatory approval. On Sunday, the senior epidemiologist in All India Institute of Medical Sciences (AIIMS) in Delhi, Dr Sanjay Rai said that the vaccine could be an iconoclast in the fight against the pandemic if it provides mucosal immunity.
The trials would be successful if this vaccine gives mucosal immunity. There are 33 vaccines all over the world but none is effective in preventing the infection. With the help of mucosal immunity, one can be protected from the entrance of Corona virus infection into their body.
The senior epidemiologist will discuss the needs to strengthen the public health system at all primary, secondary and tertiary levels at the budget session, that will be held today. He said that, this is not the last pandemic, all the people must prepare for future pandemics to handle that, we need to strengthen the public health system.
Currently, phase-3 clinical trials for intranasal vaccine booster dose have been performed at 9 states in the country. For the conduct of Phase III superiority study and Phase III booster dose study for its intranasal Covid vaccine BBV154, DCGI’s Subject Expert Committee has sanctioned an in-principle approval, earlier this month.
from Tollywood News, Tollywood Latest Updates, Telugu Cinema News https://ift.tt/2U15CM9Y7
Comments
Post a Comment